Company Analysis CymaBay Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (41.03%) is higher than the sector average (-37.33%).
Disadvantages
- Price (32.48 $) is higher than fair price (30.16 $)
- Dividends (0%) are below the sector average (0.5399%).
- Current debt level 25.12% has increased over 5 years from 1.05%.
- The company's current efficiency (ROE=-36.05%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| CymaBay Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -1.7% | 1% |
| 90 days | 0% | -40.1% | 5.9% |
| 1 year | 41% | -37.3% | 28.8% |
CBAY vs Sector: CymaBay Therapeutics, Inc. has outperformed the "Healthcare" sector by 78.36% over the past year.
CBAY vs Market: CymaBay Therapeutics, Inc. has outperformed the market by 12.22% over the past year.
Stable price: CBAY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CBAY with weekly volatility of 0.7891% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (32.48 $) is higher than the fair price (30.16 $).
Price is higher than fair: The current price (32.48 $) is 7.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (8.39) is higher than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (8.39) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (78.92) is higher than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (78.92) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-23.37) is lower than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-23.37) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 21.32% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (21.32%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-36.05%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (-36.05%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-24.24%) is lower than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (-24.24%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-59.7%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-59.7%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 13.03.2024 | Quinlan Paul T General Counsel |
Purchase | 7.89 | 329 991 | 41 824 |
| 13.03.2024 | Shah Sujal Chief Executive Officer |
Purchase | 4.72 | 656 642 | 139 119 |
| 19.01.2024 | McWherter Charles President of R&D |
Sale | 23.67 | 435 599 | 18 403 |
| 19.01.2024 | McWherter Charles President of R&D |
Purchase | 7.09 | 130 477 | 18 403 |
| 16.01.2024 | Quinlan Paul T General Counsel |
Sale | 23.58 | 117 900 | 5 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
